Flavopiridol in untreated or relapsed mantle-cell lymphoma: Results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group

Journal of Clinical Oncology

Volumn 21, Issue 9, 2003, Pages 1740-1745

  Kouroukis, C Tom ^a   Belch, Andrew ^a   Crump, Michael ^a   Eisenhauer, Elizabeth ^a   Gascoyne, Randy D ^a   Meyer, Ralph ^a   Lohmann, Reinhard ^a   Lopez, Pedro ^a   Powers, Jean ^a   Turner, Robert ^a   Connors, Joseph M ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIARRHEAL AGENT; FLAVOPIRIDOL; ANTINEOPLASTIC AGENT; FLAVONOID; PIPERIDINE DERIVATIVE;

ADULT; ARTICLE; BLOOD TOXICITY; CANADA; CANCER CENTER; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; FATIGUE; HUMAN; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; AGED; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DIARRHEA; DISEASE PROGRESSION; FATIGUE; FEMALE; FLAVONOIDS; HUMANS; INJECTIONS, INTRAVENOUS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NAUSEA; PIPERIDINES; TREATMENT OUTCOME; VOMITING;

EID: 0038473927     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2003.09.057     Document Type: Article

References (45)

1. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997
2. Harris N, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994
3. Harris NJ, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
4. Meusers P, Engelhard M, Bartels H, et al: Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
5. Weisenburger DD, Nathwani BN, Diamond LW, et al: Malignant lymphoma, intermediate lymphocytic type: A clinicopathologic study of 42 cases. Cancer 48:1415-1425, 1981
6. Bookman MA, Lardelli P, Jaffe ES, et al: Lymphocytic lymphoma of intermediate differentiation: Morphologic, immunophenotypic, and prognostic factors. J Natl Cancer Inst 82:742-748, 1990
7. The Non-Hodgkin's Lymphoma Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
8. Banks PM, Chan J, Cleary M, et al: Mantle cell lymphoma: A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 16:637-640, 1992
9. de Boer CJ, Schuuring E, Dreef E, et al: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 86:2715-2723, 1995
10. Tsujimoto Y, Jaffe E, Cossman J, et al: Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature 315:340-343, 1985
11. Tsujimoto Y, Yunis J, Onorato-Showe L, et al: Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 224:1403-1406, 1984
12. Fisher RI, Dahlberg S, Nathwani B, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): A Southwest Oncology Group Study. Blood 85:1075-1082, 1995
13. Weisenburger D, Vose J, Greiner T, et al: Mantle cell lymphoma: A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 64:190-196, 2000
14. Teodorovic I, Pittaluga S, Kluin-Nelemans JC, et al: Efficacy of four different regimens in 64 mantle-cell lymphoma cases: Clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes-European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995
15. Press OW, Grogan TM, Fisher RI: Evaluation and management of mantle cell lymphoma. Adv Leuk Lymphoma 6:3-11, 1996
16. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
17. Oinonen R, Franssila K, Teerenhovi L, et al: Mantle cell lymphoma: Clinical features, treatment and prognosis of 94 patients. Eur J Cancer 34:329-336, 1998
18. Norton AJ, Matthews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 6:249-256, 1995
19. Press OW: Treatment of mantle-cell lymphoma: Stem-cell transplantation, radioimmunotherapy, and management of mantle-cell lymphoma subsets, in Perry M (ed): American Society of Clinical Oncology Educational Book. Alexandria, VA, American Society of Clinical Oncology and Lippincott Williams & Wilkins, 2002, pp 407-415
20. Senderowicz AM: Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 15:1-9, 2001
21. Carlson BA, Dubay MM, Sausville EA, et al: Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 56:2973-2978, 1996
22. Brusselbach S, Nettelbeck DM, Sedlacek HH, et al: Cell cycle-independent induction of apoptosis by the anti-tumor drug flavopiridol in endothelial cells. Int J Cancer 77:146-152, 1998
23. Kerr JS, Wexler RS, Mousa SA, et al: Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors. Anticancer Res 19:959-968, 1999
24. Melillo G, Sausville EA, Cloud K, et al: Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 59:5433-5437, 1999
25. Konig A, Schwartz GK, Mohammad RM, et al: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 90:4307-4312, 1997
26. Kitada S, Zapata JM, Andreeff M, et al: Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 96:393-397, 2000
27. Guedez L, Quintanilla-Martinez L, Lahusen T, et al: Flavopiridol-induced apoptosis is associated with a decrease in cyclin D1 in mantle lymphoma cell lines. Presented at Am Assoc Cancer Res Annual Meeting, Philadelphia, PA, April 10-14, 1999
28. Bible KC, Kaufmann SH: Flavopiridol: A cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861, 1996
29. Semenov I, Akyuz C, Roginskaya V, et al: Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leuk Res 26:271-280, 2002
30. Parker BW, Kaur G, Nieves-Neira W, et al: Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 91:458-465, 1998
31. Arguello F, Alexander M, Sterry JA, et al: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 91:2482-2490, 1998
32. Senderowicz AM, Headlee D, Stinson SF, et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16:2986-2999, 1998
33. Senderowicz A, Messman R, Arbuck S, et al: A phase I trial of 1 hour flavopiridol, a novel cyclin dependent kinase inhibitor, in patients with advanced neoplasms. Proc Am Soc Clin Oncol 19:204a, 2000 (abstr 796)
34. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244-1253, 1999
35. National Institutes of Health, NCI: Common toxicity criteria, version 2.0. Http://ctep.info.nih.gov/reporting/ctc.html
36. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
37. Lin T, Howard O, Neuberg D, et al: Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma 43:793-797, 2002
38. Shinn C, Larsen D, Suzrez J, et al: Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cell in vitro varies based upon species drug protein binding. Blood 96:294b, 2000 (abstr 5014)
39. Jung CP, Motwani MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7:2527-2536, 2001
40. Motwani M, Delohery TM, Schwartz GK: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 5:1876-1883, 1999
41. Motwani M, Jung C, Sirotnak FM, et al: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 7:4209-4219, 2001
42. Bible KC, Kaufmann SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: The importance of sequence of administration. Cancer Res 57:3375-3380, 1997
43. Schwartz GK, O'Reilly E, Ilson D, et al: Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 20:2157-2170, 2002
44. Bible KC, Lensing J, Nelson S, et al: A phase I trial of flavopiridol combined with cisplatin in patients with advanced malignancies. Presented at Am Assoc Cancer Res Meeting, San Francisco, CA, April 6-10, 2002
45. Schwartz GK, Kaubisch A, Saltz L, et al: Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors. Clin Cancer Res 5:37545, 1999 (suppl 11, abstr 122)